C

CTI Biopharma Corp
F:CEPS

Watchlist Manager
CTI Biopharma Corp
F:CEPS
Watchlist
Price: 28 EUR Market Closed
Market Cap: 3.7B EUR

FCF Margin

-126.5%
Current
Improving
by 13%
vs 3-y average of -139.5%

Free Cash Flow (FCF) Margin shows how much cash a company generates from its sales after covering all expenses and investments. It indicates how much money is left for shareholders and debt repayment.

FCF Margin
-126.5%
=
Free Cash Flow
$-82.3m
/
Revenue
$75.8m

Free Cash Flow (FCF) Margin shows how much cash a company generates from its sales after covering all expenses and investments. It indicates how much money is left for shareholders and debt repayment.

FCF Margin
-126.5%
=
Free Cash Flow
€-82.3m
/
Revenue
$75.8m

Peer Comparison

Country Company Market Cap FCF
Margin
US
CTI Biopharma Corp
F:CEPS
3.7B EUR
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
378.3B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
178.1B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
154.2B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.2B AUD
Loading...
NL
argenx SE
XBRU:ARGX
41.9B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
46.9B USD
Loading...
No Stocks Found

Market Distribution

Lower than 88% of companies in the United States of America
Percentile
12th
Based on 15 010 companies
12th percentile
-126.5%
Low
-8 553 318% — -6%
Typical Range
-6% — 11.8%
High
11.8% — 551 750%
Distribution Statistics
the United States of America
Min -8 553 318%
30th Percentile -6%
Median 4.1%
70th Percentile 11.8%
Max 551 750%

CTI Biopharma Corp
Glance View

Market Cap
3.7B EUR
Industry
Biotechnology

CTI BioPharma Corp. began its journey with a singular focus on transforming the landscape of treatment for blood-related cancers. Established with a commitment to innovation in the biotechnology sector, the Seattle-based company has strategically positioned itself as a pivotal player in developing novel therapies for hematologic malignancies. At the heart of its operations is its flagship product, Pixuvri (pixantrone), which gained initial traction in the European market as a treatment for certain types of aggressive non-Hodgkin lymphoma. This approval represented not only a milestone for the company but also a validation of its dedicated approach in addressing critical unmet needs within oncology. The company's revenue model pivots on the successful commercialization of its pharmaceutical innovations. Through strategic collaborations and licensing agreements, CTI BioPharma seeks to broaden the distribution reach and accessibility of its treatments. By leveraging partnerships within the pharmaceutical industry, CTI has aimed to augment its research capabilities and expand its market presence. This business approach underscores a sustainable pathway to profitability by aligning its innovations directly with the needs of healthcare providers and patients, thus ensuring that its scientific advances translate into tangible therapeutic options in the oncology space. By continually refining its product portfolio, the company maintains a dynamic stance in a rapidly evolving market, safeguarding its position and ensuring its growth trajectory.

CEPS Intrinsic Value
Not Available
C
What is Free Cash Flow Margin?
Free Cash Flow (FCF) Margin shows how much cash a company generates from its sales after covering all expenses and investments. It indicates how much money is left for shareholders and debt repayment.
How is FCF Margin calculated?

FCF Margin is calculated by dividing the Free Cash Flow by the Revenue.

FCF Margin
-126.5%
=
Free Cash Flow
$-82.3m
/
Revenue
$75.8m
What is CTI Biopharma Corp's current FCF Margin?

The current FCF Margin for CTI Biopharma Corp is -126.5%, which is above its 3-year median of -139.5%.

How has FCF Margin changed over time?

Over the last 3 years, CTI Biopharma Corp’s FCF Margin has increased from -1 416.7% to -126.5%. During this period, it reached a low of -4 730.9% on Mar 31, 2022 and a high of -117.8% on May 1, 2023.

Back to Top